RU2726367C2 - Фармацевтические комбинации для лечения злокачественной опухоли - Google Patents

Фармацевтические комбинации для лечения злокачественной опухоли Download PDF

Info

Publication number
RU2726367C2
RU2726367C2 RU2018137687A RU2018137687A RU2726367C2 RU 2726367 C2 RU2726367 C2 RU 2726367C2 RU 2018137687 A RU2018137687 A RU 2018137687A RU 2018137687 A RU2018137687 A RU 2018137687A RU 2726367 C2 RU2726367 C2 RU 2726367C2
Authority
RU
Russia
Prior art keywords
inhibitor
lymphoma
bcl
cancer
formula
Prior art date
Application number
RU2018137687A
Other languages
English (en)
Russian (ru)
Other versions
RU2018137687A3 (enExample
RU2018137687A (ru
Inventor
Ричард КЛИНГХОФФЕР
Джойоти ДЕЙ
Original Assignee
Пресидж Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пресидж Байосайенсиз, Инк. filed Critical Пресидж Байосайенсиз, Инк.
Publication of RU2018137687A3 publication Critical patent/RU2018137687A3/ru
Publication of RU2018137687A publication Critical patent/RU2018137687A/ru
Application granted granted Critical
Publication of RU2726367C2 publication Critical patent/RU2726367C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018137687A 2016-03-28 2017-03-28 Фармацевтические комбинации для лечения злокачественной опухоли RU2726367C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
US62/314,356 2016-03-28
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020121147A Division RU2850269C2 (ru) 2016-03-28 2020-06-26 Фармацевтические комбинации для лечения злокачественной опухоли

Publications (3)

Publication Number Publication Date
RU2018137687A3 RU2018137687A3 (enExample) 2020-04-29
RU2018137687A RU2018137687A (ru) 2020-04-29
RU2726367C2 true RU2726367C2 (ru) 2020-07-13

Family

ID=59966407

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018137687A RU2726367C2 (ru) 2016-03-28 2017-03-28 Фармацевтические комбинации для лечения злокачественной опухоли

Country Status (13)

Country Link
US (5) US11135198B2 (enExample)
EP (1) EP3436002B1 (enExample)
JP (3) JP7114478B2 (enExample)
KR (5) KR102545392B1 (enExample)
CN (1) CN109689047B (enExample)
AU (4) AU2017241914B2 (enExample)
CA (2) CA3018932C (enExample)
IL (3) IL312398A (enExample)
MX (3) MX2018011666A (enExample)
NZ (1) NZ747404A (enExample)
RU (1) RU2726367C2 (enExample)
WO (1) WO2017172826A1 (enExample)
ZA (2) ZA201806819B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840687C (en) 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
IL312398A (en) * 2016-03-28 2024-06-01 Presage Biosciences Inc Pharmaceutical combinations for cancer treatment
EP3703755B1 (en) * 2017-10-31 2024-07-31 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
WO2020036995A1 (en) * 2018-08-14 2020-02-20 Mei Pharma, Inc. Combination therapy
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
CA3136599A1 (en) 2019-04-11 2020-10-15 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
AU2020362194A1 (en) * 2019-10-08 2022-05-19 Dana-Farber Cancer Institute, Inc. A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases
EP4106760A4 (en) * 2020-05-07 2024-03-27 Recurium IP Holdings, LLC COMBINATIONS
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
IL302925A (en) * 2020-11-19 2023-07-01 Mei Pharma Inc Treatment of kras mutant cancers
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
JP2024516097A (ja) * 2021-04-10 2024-04-12 メイ ファーマ，インク． ボルシクリブ（ｖｏｒｕｃｉｃｌｉｂ）投与レジメンおよびこれを含む治療方法
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
US20130237582A1 (en) * 2010-11-19 2013-09-12 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
US20140080838A1 (en) * 2012-09-20 2014-03-20 Memorial Sloan-Kettering Cancer Center Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PT1768966E (pt) 2004-06-17 2012-05-23 Infinity Discovery Inc Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CN101175738B (zh) 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
MX2007014783A (es) 2005-05-24 2008-02-19 Abbott Lab Activadores de apoptosis.
US8563596B2 (en) 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
JP5688288B2 (ja) * 2007-05-15 2015-03-25 ピラマル エンタープライジーズ リミテッド がんの処置のための相乗的な医薬の組合せ
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
ES2959198T3 (es) * 2012-07-24 2024-02-21 Avalyn Pharma Inc Compuestos análogos de pirfenidona y piridona en aerosol
JP6347793B2 (ja) 2013-01-16 2018-06-27 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法
CN105164117B (zh) * 2013-03-14 2019-02-01 欧尼斯治疗公司 二肽和三肽环氧酮蛋白酶抑制剂
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
IL312398A (en) 2016-03-28 2024-06-01 Presage Biosciences Inc Pharmaceutical combinations for cancer treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
US20130237582A1 (en) * 2010-11-19 2013-09-12 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
US20140080838A1 (en) * 2012-09-20 2014-03-20 Memorial Sloan-Kettering Cancer Center Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOGENBERGER J. et al. Combined venetoclax and alvocidib in acute myeloid leukemia // Oncotarget. 2017. Vol. 8. P. 107206-107222. *
ХАРКЕВИЧ Д.А. Фармакология. М.: "Медицина". 1987г. С. 51. *

Also Published As

Publication number Publication date
KR102599512B1 (ko) 2023-11-07
RU2020121147A (ru) 2021-11-03
AU2021273532B2 (en) 2024-02-01
IL295472A (en) 2022-10-01
NZ757763A (en) 2025-07-25
JP2024038227A (ja) 2024-03-19
US20200383948A1 (en) 2020-12-10
KR20230156443A (ko) 2023-11-14
CA3018932A1 (en) 2017-10-05
US11135198B2 (en) 2021-10-05
MX2022002318A (es) 2022-04-06
WO2017172826A1 (en) 2017-10-05
KR20230021155A (ko) 2023-02-13
KR20210088016A (ko) 2021-07-13
ZA202107579B (en) 2025-03-26
KR20190039878A (ko) 2019-04-16
KR102275758B1 (ko) 2021-07-12
IL295472B1 (en) 2024-06-01
IL261824B2 (en) 2023-02-01
MX2018011666A (es) 2019-07-08
CN109689047B (zh) 2025-03-21
JP7416872B2 (ja) 2024-01-17
IL261824A (en) 2018-10-31
AU2020201247A1 (en) 2020-03-12
RU2018137687A3 (enExample) 2020-04-29
AU2024200194A1 (en) 2024-02-01
US20220023261A1 (en) 2022-01-27
KR20230093360A (ko) 2023-06-27
IL261824B (en) 2022-10-01
US12121508B2 (en) 2024-10-22
CA3103604A1 (en) 2017-10-05
JP2022141916A (ja) 2022-09-29
EP3436002A1 (en) 2019-02-06
RU2018137687A (ru) 2020-04-29
KR102494039B1 (ko) 2023-01-30
AU2017241914B2 (en) 2020-02-27
IL295472B2 (en) 2024-10-01
JP7114478B2 (ja) 2022-08-08
US20210283104A1 (en) 2021-09-16
AU2017241914A1 (en) 2018-11-08
CA3103604C (en) 2023-09-26
IL312398A (en) 2024-06-01
CA3018932C (en) 2021-10-26
KR102545392B1 (ko) 2023-06-20
ZA201806819B (en) 2022-03-30
EP3436002B1 (en) 2025-11-05
US20190275004A1 (en) 2019-09-12
CN109689047A (zh) 2019-04-26
MX2022011750A (es) 2022-10-18
AU2021273532A1 (en) 2021-12-16
US12171744B2 (en) 2024-12-24
US20250221961A1 (en) 2025-07-10
EP3436002A4 (en) 2019-12-04
JP2019514854A (ja) 2019-06-06
NZ747404A (en) 2020-03-27
AU2020201247B2 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US12121508B2 (en) Pharmaceutical combinations for the treatment of cancer
IL250112B2 (en) Aqueous formulation comprising paracetamol and ibuprofen
RU2850269C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
HK40007742A (en) Pharmaceutical combinations for the treatment of cancer
NZ786330A (en) Pharmaceutical combinations for the treatment of cancer
HK40004148A (en) Pharmaceutical combinations for the treatment of cancer
HK40004148B (en) Pharmaceutical combinations for the treatment of cancer